[Advances on the role of pegaspargase in the treatment of childhood leukemia].

The chemotherapy agent L-asparaginase (L-asp) has been an important part of acute lymphoblastic leukemia therapy for over 30 years. It is evident that L-asp has a long-term curative effect. However, L-asp is associated with high incidence of adverse reactions. This has prompted the development of pegylated asparaginase (PEG-asp), which has undergone extensive testing. Apparently, PEG-asp has a prolonged half-life with a better tolerance profile while retaining the antileukemic effect. In this review, we attempt to outline the history of clinical application of L-asp, the pharmacological and clinical potential of various preparations of L-asp, the development of PEG-asp, and the clinical application and adverse events of PEG-asp. The literatures reviewed in this article is collected through online search of the major databases both in English and Chinese.
AuthorsLi Liu, Xiao-Tian Xie
JournalZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics (Zhongguo Dang Dai Er Ke Za Zhi) Vol. 16 Issue 2 Pg. 155-60 (Feb 2014) ISSN: 1008-8830 [Print] China
PMID24568909 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • pegaspargase
  • Polyethylene Glycols
  • Asparaginase
  • Antineoplastic Agents (therapeutic use)
  • Asparaginase (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Blood Coagulation Disorders (chemically induced)
  • Humans
  • Pancreatitis (chemically induced)
  • Polyethylene Glycols (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: